App-Quantinova.ai

A molecular measure of inflammation in IBD patients based on transcriptional profiles from 2495 intestinal biopsies

R Huang - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

N/A

Mucosal micoRNA profiles predict response to autologous stem-cell transplantation in Crohn’s disease

A Lewis - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

N/A

Host–microbial crosstalk in the pathogenesis of inflammation and cancer in primary sclerosing cholangitis

M Neyazi - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Primary sclerosing cholangitis

N/A

A novel mechanism of colonic epithelial-T-cell cross-talk is dysregulated in IBD

R J Dart - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Endoscopic and deep remission at 1 year prevents disease progression in early Crohn’s disease: long-term data from CALM

C Yzet - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

N/A

Analysing intestinal organoids in a multi-omics, systems biology framework to investigate functional processes affected in Crohn’s disease due to autophagy impairment

L Gul - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

N/A

Cost analysis in a prospective European population-based inception cohort: is there a cost-saving effect of biological therapy?

J Burisch - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Dynamic shifts in the balance of gut homing Treg and Th17 cells play a critical role in ulcerative colitis and may predict response to vedolizumab therapy

S Hermangild Kottoor - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

Entyvio

The regulatory landscape of intestinal cells—investigating the transcriptional effect of autophagy impairment observed in Crohn’s disease using organoid and network biology approaches

A Treveil - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

N/A

Lymphocyte activation gene (LAG)-3 on T cells is a potential therapeutic target in ulcerative colitis

S Slevin - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

N/A

Serum N-glycomic biomarkers predict treatment escalation in inflammatory bowel disease

A Shubhakar - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

OSM neutralisation in IBD mucosal explant cultures reduces pro-inflammatory cytokine production

A Vossenkamper - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

Prednisolone

Drugs that modulate histone acetylation disrupt TGF-β-signalling and reduce collagen I expression in models of stricturing Crohn’s disease

A Lewis - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

N/A

Factors associated with life satisfaction in people with Crohn’s disease and ulcerative colitis: results from the national 2018 Crohn’s and Colitis UK Inflammatory Bowel Disease Quality of Life Survey

G Rowse - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

Maternal obstetric outcomes in women with IBD compared with the general population

G Lever - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Pregnancy outcomes in IBD patients treated with vedolizumab, anti-TNF, or conventional therapy

A Moens - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Entyvio

A vedolizumab specific four-gene colonic signature accurately predicting future endoscopic remission in patients with inflammatory bowel disease

B Verstockt - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

Entyvio

Amiselimod, a selective S1P receptor modulator in Crohn’s disease patients: a proof-of-concept study

G DHaens - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

MT1303

The interleukin 22 transcriptional programme is activated in human colonic inflammation and associated to anti-TNFα primary non-response in Crohn’s

P Pavlidis - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Interleukin

A nationwide cohort study of colectomy rates for ulcerative colitis during the introduction of biologic therapy

G Worley - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

Infliximab

Filters

45280 Abstracts